DB
MDLN

Dmitry Balyasny’s Medline Inc MDLN Stock Holding History

Dmitry Balyasny’s Portfolio MDLN Stock Details MDLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-618,293
Closed -$27.5M – 3642
2026
Q1 		$27.5M Buy
618,293
+382,037
+162% +$16.9M 0.04% 563
2025
Q4 		$9.92M Buy
+236,256
New +$9.98M 0.01% 1032

Other funds holding MDLN

CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
HFCIX
H&F Corporate Investors X San Francisco, California $2.8B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $16.4B AUM 99.7% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dmitry Balyasny's MDLN Position: Q2 2026 in Review

Dmitry Balyasny sold out of Medline Inc (MDLN) in Q2 2026, closing a stake of 618,293 shares — an estimated $27.5M sold.

Dmitry Balyasny first reported a position in MDLN in Q4 2025 and held it in 2 quarters. The position peaked at $27.5M in Q1 2026. 405 funds tracked by Wall St. Rank hold MDLN as of Q2 2026.

  • Dmitry Balyasny reported no remaining Medline Inc position as of Q2 2026 after selling out during the quarter.
  • Dmitry Balyasny sold 618,293 Medline Inc shares in Q2 2026, an estimated $27.5M.
  • Dmitry Balyasny first reported a position in Medline Inc in Q4 2025 and held it in 2 quarters.
  • Dmitry Balyasny's Medline Inc position peaked at $27.5M in Q1 2026.
  • 405 funds tracked by Wall St. Rank held Medline Inc as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.